Patents Examined by Jennifer Dunston
  • Patent number: 11566230
    Abstract: Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating the genetically modified cells are provided herein. The universal donor cells comprise at least one genetic modification within or near a gene that encodes one or more MHC-I or MHC-II human leukocyte antigens or a component or a transcriptional regulator of a MHC-I or MHC-II complex, wherein genetic modification comprises an insertion of a polynucleotide encoding a tolerogenic factor and/or survival factor. The universal donor cells may further comprise at least one genetic modification within or near a gene that encodes a survival factor, wherein the genetic modification comprises an insertion of a polynucleotide encoding a second tolerogenic factor and/or a different survival factor.
    Type: Grant
    Filed: December 31, 2021
    Date of Patent: January 31, 2023
    Assignee: CRISPR THERAPEUTICS AG
    Inventors: Alireza Rezania, Valentin Sluch
  • Patent number: 11542528
    Abstract: Gene therapy compositions and methods are provided that make use of transposases and/or chimeric transposases for targeted transposition, including engineered enzymes and nucleic acids encoding the same. The provided compositions and methods are suitable of treating, for example, an inherited or acquired disease in a patient, as well as treating and/or mitigating a variety of diseases.
    Type: Grant
    Filed: February 11, 2022
    Date of Patent: January 3, 2023
    Assignee: Saliogen Therapeutics, Inc.
    Inventors: Joseph J. Higgins, Scott McMillan, Ray Tabibiazar
  • Patent number: 11535871
    Abstract: Described herein are methods and compositions for genomic editing. Endonucleases for genomic editing involve inducing breaks in double stranded DNA, for which knock-ins are notoriously inefficient for relying on random integration of homologous DNA sequences into the break site by repair proteins. To address these issues, described herein are novel recombinant fusion proteins that actively recruit linear DNA inserts in closer proximity to the genomic cleavage site, increasing integration efficiency of large DNA fragments into the genome. Such improvements to genomic editing technology allow one to use lower linear DNA concentrations without sacrificing efficiency and can be further combined with other features, such as fluorescent protein reporting systems.
    Type: Grant
    Filed: May 13, 2016
    Date of Patent: December 27, 2022
    Assignee: University of Southern California
    Inventors: Jason Junge, Timothy Hunt, Scott E. Fraser
  • Patent number: 11535889
    Abstract: Described herein is an adapter comprising a population of first oligonucleotides, a second oligonucleotide and a third oligonucleotide, wherein the first oligonucleotides, the second oligonucleotide and the third oligonucleotide are hybridized together to produce a complex that comprises: (i) a first end comprising a transposase recognition sequence, (ii) a central single-stranded region of variable sequence and (iii) a second end comprising sequences that are non-complementary. A method, as well as a kit for practicing the method, are also provided.
    Type: Grant
    Filed: March 7, 2019
    Date of Patent: December 27, 2022
    Assignee: Agilent Technologies, Inc.
    Inventors: Robert A. Ach, Nicholas M. Sampas, Brian Jon Peter
  • Patent number: 11535835
    Abstract: Provided herein are Class 2 Type V CRISPR:gNA systems comprising Class 2 Type V CRISPR polypeptides (e.g. CasX), guide nucleic acids (gNA), and optionally donor template nucleic acids useful in the modification of a RHO gene. The systems are also useful for introduction into cells, for example eukaryotic cells having mutations in the rhodopsin protein. Also provided are methods of using such systems to modify cells having such mutations and utility in methods of treatment of a subject with a RHO-related disease, such as retinitis pigmentosa.
    Type: Grant
    Filed: September 23, 2021
    Date of Patent: December 27, 2022
    Assignee: Scribe Therapeutics Inc.
    Inventors: Benjamin Oakes, Hannah Spinner, Sarah Denny, Brett T. Staahl, Kian Taylor, Katherine Baney, Isabel Colin, Maroof Adil, Cole Urnes, Sean Higgins
  • Patent number: 11479766
    Abstract: A method of labeling, and optionally enriching, for a population of target RNA molecules in a mixture of RNAs is provided. In some embodiments, the method may comprise (a) adding a label to the 5? end of 5?-diphosphorylated or 5?-triphosphorylated target RNA molecules in a sample by incubating the sample with labeled GTP and a capping enzyme; and (b) optionally enriching for target RNA comprising the affinity tag-labeled GMP using an affinity matrix that binds to the affinity tag. The label may be an oligonucleotide, which may further comprise an affinity group attached either internally or at 5? or 3? end of the oligonucleotide where the oligonucleotide label may be added directly, or indirectly via a reaction with a reactive group to the target RNA.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: October 25, 2022
    Assignee: New England Biolabs, Inc.
    Inventors: Ira Schildkraut, Laurence Ettwiller, Ivan R. Correa, Jr., George Tzertzinis, John Buswell, Madalee G. Wulf
  • Patent number: 11473055
    Abstract: The current teachings are directed to virus free cells lines derived from virus-contaminated starting material, such as an organism or a cell line. Methods for obtaining virus free cell lines obtained from virus-contaminated starting material are also provided. Exemplary virus free cell lines include: cell lines derived from a Spodoptera frugiperda cell line contaminated with Sf-rhabdovirus, wherein the cell lines lack Sf-rhabdovirus; and cell lines derived from a Trichoplusia ni cell line contaminated with an alphanodavirus, wherein the cell line lacks an alphanodavirus.
    Type: Grant
    Filed: November 1, 2016
    Date of Patent: October 18, 2022
    Assignee: GLYCOBAC, LLC
    Inventors: Ajay Maghodia, Christoph Geisler, Donald Jarvis
  • Patent number: 11462298
    Abstract: Provided herein are methods, processes and apparatuses for non-invasive assessment of genetic variations that make use of decision analyses. The decision analyses sometimes include segmentation analyses and/or odds ratio analyses.
    Type: Grant
    Filed: April 29, 2020
    Date of Patent: October 4, 2022
    Assignee: Sequenom, Inc.
    Inventors: Chen Zhao, Zeljko Dzakula, Cosmin Deciu, Sung Kyun Kim, Amin R. Mazloom, Gregory Hannum, Mathias Ehrich
  • Patent number: 11459584
    Abstract: A gene sequence of recombinant human type II mitochondrial dynein-like GTPase having a nucleotide sequence shown in SEQ ID NO: 1 and uses thereof. A fusion nucleic acid comprising a nucleic acid encoding human type II mitochondrial dynein-like GTPase. A recombinant expression vector comprising the nucleic acid or a fusion nucleic acid. A transformant by which the nucleic acid or the fusion nucleic acid is introduced into a host. A non-human mammalian ADOA model based on the inactivation of the gene of type II mitochondrial dynein-like GTPase, which can effectively improve the pathological manifestations of ADOA using a recombinant expression vector encoding the human type II mitochondrial dynein-like GTPase. The expression level of the nucleic acid encoding the human type II mitochondrial dynein-like GTPase is higher, therefore, more human type II mitochondrial dynein-like GTPase can be obtained in the mitochondria. which can better treat eye diseases such as ADOA.
    Type: Grant
    Filed: February 23, 2021
    Date of Patent: October 4, 2022
    Assignee: Wuhan Neurophth Biotechnology Limited Company
    Inventor: Bin Li
  • Patent number: 11453880
    Abstract: Disclosed is a double-stranded oligonucleotide decoy including two transcription factor-binding sites, while keeping its size small. The double-stranded oligonucleotide decoy showing binding affinities for two transcription factors includes a first binding site for a first transcription factor and a second binding site for a second transcription factor. A first strand including the sense strand of the first binding site and a second strand including the sense strand of the second binding site are hybridized to form a double strand in which the sense strand of the first binding site and the sense strand of the second binding site are at least partly hybridized.
    Type: Grant
    Filed: September 9, 2016
    Date of Patent: September 27, 2022
    Assignees: ANGES, INC., GENEDESIGN, INC.
    Inventors: Ryuichi Morishita, Takashi Miyake, Tetsuo Miyake, Takahiro Nakazawa, Makoto Sakaguchi, Satoshi Inoue, Ryoji Ueki
  • Patent number: 11453875
    Abstract: Presented herein are methods and compositions surface-based tagmentation. In particular embodiments, methods of preparing an immobilized library of fragmented and tagged DNA molecules on a solid surface are presented. In particular embodiments, the solid surface comprises immobilized transposomes in a dried format, suitable for reconstitution upon contact with liquid, such as a liquid sample.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: September 27, 2022
    Assignee: ILLUMINA CAMBRIDGE LIMITED
    Inventors: Niall Anthony Gormley, Avgousta Ioannou, Rosamond Jackson, Natalie Morrell
  • Patent number: 11447770
    Abstract: Compositions and methods are provided herein for conducting prime editing of a target DNA molecule (e.g., a genome) that enables the incorporation of a nucleotide change and/or targeted mutagenesis. The compositions include fusion proteins comprising nucleic acid programmable DNA binding proteins (napDNAbp) and a polymerase (e.g., reverse transcriptase), which is guided to a specific DNA sequence by a modified guide RNA, named a PEgRNA. The PEgRNA has been altered (relative to a standard guide RNA) to comprise an extended portion that provides a DNA synthesis template sequence which encodes a single strand DNA flap which is synthesized by the polymerase of the fusion protein and which becomes incorporated into the target DNA molecule.
    Type: Grant
    Filed: March 31, 2021
    Date of Patent: September 20, 2022
    Assignees: The Broad Institute, Inc., President and Fellows of Harvard College
    Inventors: David R. Liu, Andrew Vito Anzalone, Gregory Newby, Kelcee Everette
  • Patent number: 11434530
    Abstract: Methods, devices and systems for analyzing precious samples of cells, including single cells are provided. The methods, devices, and systems in various embodiments of the invention are used to assess genomic heterogeneity, which has been recognized as a central feature of many cancers and plays a critical role in disease initiation, progression, and response to treatment. The methods devices and systems are also used to analyze embryonic biopsies for preimplantation genetic diagnosis (PGD). In one embodiment, the devices, systems and methods provided herein allow for the construction of genomic and RNA-seq libraries without a pre-amplification step.
    Type: Grant
    Filed: April 16, 2020
    Date of Patent: September 6, 2022
    Assignee: THE UNIVERSITY OF BRITISH COLUMBIA
    Inventors: Carl Lars Genghis Hansen, Hans Zahn, Jens Huft, Marinus Theodorus Johannes Van Loenhout, Kaston Leung, Bill Kengli Lin, Anders Klaus, Samuel Alves Jana Rodrigues Aparicio, Sohrab Prakash Shah, Adi Steif
  • Patent number: 11427819
    Abstract: A composition used in targeted mutagenesis is provided, which includes a first expression cassette comprising a nucleotide sequence which encodes a CAS9 endonuclease; a second expression cassette comprising a nucleotide sequence which encodes a guide RNA sequence, wherein the guide RNA sequence is complementary to a target genome nucleotide sequence in a cell; and a third expression cassette comprising a nucleotide sequence which encodes a Trex2 exonuclease (Trex2) gene. The first, second, and third expression cassettes may be a part or a portion of one or more expression vectors.
    Type: Grant
    Filed: December 5, 2018
    Date of Patent: August 30, 2022
    Assignee: CITY OF HOPE
    Inventors: Jeremy M. Stark, Diana Yanez
  • Patent number: 11379729
    Abstract: Methods and systems for encoding digital information in nucleic acid (e.g., deoxyribonucleic acid) molecules without base-by-base synthesis, by encoding bit-value information in the presence or absence of unique nucleic acid sequences within a pool, comprising specifying each bit location in a bit-stream with a unique nucleic sequence and specifying the bit value at that location by the presence or absence of the corresponding unique nucleic acid sequence in the pool But, more generally, specifying unique bytes in a bytestream by unique subsets of nucleic acid sequences. Also disclosed are methods for generating unique nucleic acid sequences without base-by-base synthesis using combinatorial genomic strategies (e.g., assembly of multiple nucleic acid sequences or enzymatic-based editing of nucleic acid sequences).
    Type: Grant
    Filed: August 31, 2020
    Date of Patent: July 5, 2022
    Assignee: CATALOG TECHNOLOGIES, INC.
    Inventors: Nathaniel Roquet, Hyunjun Park, Swapnil P. Bhatia
  • Patent number: 11369691
    Abstract: The present invention relates to a pharmaceutical composition comprising a modified mRNA that is stabilised by sequence modifications and optimised for translation. The pharmaceutical composition according to the invention is particularly well suited for use as an inoculating agent, as well as a therapeutic agent for tissue regeneration. In addition, a process is described for determining sequence modifications that promote stabilisation and translational efficiency of modified mRNA of the invention.
    Type: Grant
    Filed: January 25, 2016
    Date of Patent: June 28, 2022
    Assignee: CureVac AG
    Inventors: Florian Von Der Mülbe, Ingmar Hoerr, Steve Pascolo
  • Patent number: 11352639
    Abstract: Produced the gene therapy DNA vectors based on the gene therapy DNA vector for treatment of diseases associated with disorders of osteogenesis, formation and regeneration of bone and cartilage tissues, including, in case of bone fractures, increased brittleness of bones, reduction of bones mineralisation, for improvement in osteoinduction of bone implants. The gene therapy DNA vector contains the coding region of the COL1A1, COL1A2, BMP2 or BMP7 therapeutic genes. Methods of producing or use the gene therapy DNA vector carrying therapeutic genes. Escherichia coli strain SCS110-AF/VTvaf17-COL1A1, SCS110-AF/VTvaf17-COL1A2, SCS110-AF/VTvaf17-BMP2 or SCS110-AF/VTvaf17-BMP7 obtains by the method described above carrying gene therapy DNA vector VTvaf17-COL1A1, VTvaf17-COL1A2, VTvaf17-BMP2 or VTvaf17-BMP7. The method of producing the gene therapy DNA vector carrying COL1A1, or COL1A2, or BMP2, or BMP7 therapeutic gene uses on an industrial scale.
    Type: Grant
    Filed: August 14, 2019
    Date of Patent: June 7, 2022
    Assignees: OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTJU “ALLEL TSENTR INNOVATSIONNYKH BIOTEKHNOLOGY”, OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTJU “PRORYVNYE INNOVATSIONNYE TEKHNOLOGII”, CELL AND GENE THERAPY LTD
    Inventors: Natalia Savelieva, Vasily Nikolaevich Lazarev, Galina Vasilievna Shmarina
  • Patent number: 11339444
    Abstract: A method for detecting genes sensitive to low-level ionizing radiation and genes detected by the method. More specifically, genes sensitive to low-level ionizing radiation and related to suppressing thymic cancer, discovered in a carcinogenic entity and verified in a normal entity are detected by subjecting a cancerous AKR/J mouse and a normal ICR mouse to low-level radiation. Thymus is collected therefrom, immunogenic and apoptotic genes are classified via microarray processing of the thymus. The genes are amplified and the levels of gene expression are measured. Thus, a gene having a specific reaction to radiation can be accurately detected by preventing the interference of confounding variables.
    Type: Grant
    Filed: November 16, 2018
    Date of Patent: May 24, 2022
    Assignee: KOREA HYDRO & NUCLEAR POWER CO., LTD
    Inventors: Hee Sun Kim, Seung Jin Choi, Moo Hyun Choi, Jin Jong Bong, Seok Cheol Shin
  • Patent number: 11339443
    Abstract: A method for detecting genes sensitive to low-level ionizing radiation and genes detected by the method. More specifically, genes sensitive to low-level ionizing radiation and related to suppressing thymic cancer, discovered in a carcinogenic entity and verified in a normal entity are detected by subjecting a cancerous AKR/J mouse and a normal ICR mouse to low-level radiation. Thymus is collected therefrom, immunogenic and apoptotic genes are classified via microarray processing of the thymus. The genes are amplified and the levels of gene expression are measured. Thus, a gene having a specific reaction to radiation can be accurately detected by preventing the interference of confounding variables.
    Type: Grant
    Filed: November 16, 2018
    Date of Patent: May 24, 2022
    Assignee: KOREA HYDRO & NUCLEAR POWER CO., LTD.
    Inventors: Hee Sun Kim, Seung Jin Choi, Moo Hyun Choi, Jin Jong Bong, Seok Cheol Shin
  • Patent number: 11339445
    Abstract: A method for detecting genes sensitive to low-level ionizing radiation and genes detected by the method. More specifically, genes sensitive to low-level ionizing radiation and related to suppressing thymic cancer, discovered in a carcinogenic entity and verified in a normal entity are detected by subjecting a cancerous AKR/J mouse and a normal ICR mouse to low-level radiation. Thymus is collected therefrom, immunogenic and apoptotic genes are classified via microarray processing of the thymus. The genes are amplified and the levels of gene expression are measured. Thus, a gene having a specific reaction to radiation can be accurately detected by preventing the interference of confounding variables.
    Type: Grant
    Filed: November 16, 2018
    Date of Patent: May 24, 2022
    Assignee: KOREA HYDRO & NUCLEAR POWER CO., LTD
    Inventors: Hee Sun Kim, Seung Jin Choi, Moo Hyun Choi, Jin Jong Bong, Seok Cheol Shin